21 September 2021

Biochemical recurrence occurs in >20% of treated prostate cancer patients, mainly due to metastatic disease (>80%). In the multicenter clinical study ADOPT, 280 men with oligo-recurrent prostate cancer from 10 participating hospitals in the Netherlands are randomized to receive standard metastasis-targeted radiotherapy or metastasis-targeted radiotherapy in combination with 6 months of ADT. Biomaterial from eligible ADOPT patients will be used to establish the ADOPT biobank. Patients eligible for the ADOPT study will be asked to consent to blood collection prior to treatment and during 6 and 12 month follow-up. The ADOPT biobank plans to use new technology to identify and validate circulating tumor DNA (ctDNA) and extracellular vesicle (EV) biomarker. These will then be used as predictive and prognostic tools to improve the timing of clinical treatment and to more accurately monitor treatment response.

  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl)

19 July 2022

The Ministry of Health, Welfare and Sport (VWS) is currently preparing a Control over Human Biomaterials Act [Wet zeggenschap lichaamsmateriaal] (Wzl) which will serve in the future as a specific legal framework for the (further) use of body tissue for medical scientific research.

read more

Health-RI annual report

19 July 2022

Health-RI has presented the 2021 annual report. In this report they outline an overview of recent activities and results of the past year 2021 (in Dutch).

read more

SPIDI sub-biobank

19 July 2022

The SPIDI collection aims to assess the prognostic value of MRI-DWI (new form of MRI research) and biomarkers (brain-specific proteins in cerebrospinal fluid) in the first 24 hours after the occurrence of a spinal cord injury as a result of trauma.

read more

MyCoS sub-biobank

8 April 2022 The Radboud Biobank has added one new sub-biobank to the collection: MyCoS. read more